Presentation and Management of HHV6 Infection in a 32 Days Old Baby

El Ahmar Malak, Srour Sara, Hanna pielly, Beih Farah, Sacy Robert, I. Nada
{"title":"Presentation and Management of HHV6 Infection in a 32 Days Old Baby","authors":"El Ahmar Malak, Srour Sara, Hanna pielly, Beih Farah, Sacy Robert, I. Nada","doi":"10.31031/RPN.2018.03.000557","DOIUrl":null,"url":null,"abstract":"Background: Human herpesvirus 6 (HHV-6), commonly known to cause the childhood disease roseola and nonspecific viral illness, has been known to cause serious neurological complications including fever induced seizures and encephalitis with possible long-term sequelae especially in immunocompromised patients. Purposes: To report a rare case of HHV-6 meningitis in a 32-day old male infant and the challenging therapeutic approach required to treat and manage this condition. Case summary: A 32-day old male infant presented with one episode of high-grade fever and bulging anterior fontanel in the absence of skin rashes. Blood tests were normal but lumbar puncture done at admission revealed lymphocytic pleocytosis secondary to acute HHV-6 confirmed by CSF PCR. Data indicating appropriate treatment in this age group is limited. In this case, the patient received Ganciclovir IV for 14 days and showed clinical improvement. Conclusion: Treatment of HHV-6 meningitis with ganciclovir is recommended for immunocompromised patients, including immune deficient patients, and those receiving chemotherapy or prolonged course of steroid. However, literature does not support any specific treatment for immunocompetent children. No data or clear recommendations are currently available for the treatment of neonates with HHV-6 meningitis. Should neonates be thought of as immunocompromised hosts and be treated with Ganciclovir or should they only receive supportive treatment? More studies are required to have an evidence based antiviral treatment in this age group.","PeriodicalId":153075,"journal":{"name":"Research in Pediatrics & Neonatology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Pediatrics & Neonatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31031/RPN.2018.03.000557","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Human herpesvirus 6 (HHV-6), commonly known to cause the childhood disease roseola and nonspecific viral illness, has been known to cause serious neurological complications including fever induced seizures and encephalitis with possible long-term sequelae especially in immunocompromised patients. Purposes: To report a rare case of HHV-6 meningitis in a 32-day old male infant and the challenging therapeutic approach required to treat and manage this condition. Case summary: A 32-day old male infant presented with one episode of high-grade fever and bulging anterior fontanel in the absence of skin rashes. Blood tests were normal but lumbar puncture done at admission revealed lymphocytic pleocytosis secondary to acute HHV-6 confirmed by CSF PCR. Data indicating appropriate treatment in this age group is limited. In this case, the patient received Ganciclovir IV for 14 days and showed clinical improvement. Conclusion: Treatment of HHV-6 meningitis with ganciclovir is recommended for immunocompromised patients, including immune deficient patients, and those receiving chemotherapy or prolonged course of steroid. However, literature does not support any specific treatment for immunocompetent children. No data or clear recommendations are currently available for the treatment of neonates with HHV-6 meningitis. Should neonates be thought of as immunocompromised hosts and be treated with Ganciclovir or should they only receive supportive treatment? More studies are required to have an evidence based antiviral treatment in this age group.
32天大婴儿HHV6感染的表现和处理
背景:人类疱疹病毒6 (HHV-6),通常被认为是引起儿童疾病玫瑰疹和非特异性病毒性疾病,已经被认为是引起严重的神经系统并发症,包括发热引起的癫痫和脑炎,特别是免疫功能低下的患者可能有长期的后遗症。目的:报告一例罕见的32天大男婴HHV-6脑膜炎病例,以及治疗和管理这种疾病所需的具有挑战性的治疗方法。病例总结:一个32天大的男婴,在没有皮疹的情况下,表现为一次高热和前囟门隆起。血液检查正常,但入院时腰椎穿刺显示继发于急性HHV-6的淋巴细胞增多症,经CSF PCR证实。数据表明该年龄组的适当治疗是有限的。本例患者接受更昔洛韦治疗14天,临床有所改善。结论:更昔洛韦治疗HHV-6脑膜炎推荐用于免疫功能低下患者,包括免疫缺陷患者,接受化疗或延长类固醇疗程的患者。然而,文献不支持对免疫功能正常的儿童进行任何特异性治疗。目前尚无治疗新生儿HHV-6型脑膜炎的数据或明确建议。新生儿是否应该被认为是免疫功能低下的宿主,应该用更昔洛韦治疗,还是应该只接受支持性治疗?需要更多的研究来为这一年龄组提供基于证据的抗病毒治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信